Cargando…
Bionanomaterials for diagnosis and therapy of SARS-CoV-2
Coronavirus disease 2019 (COVID-19) was first detected in December 2019 in China and has caused a global pandemic affecting 202 nations around the world. It is caused by a new pathogen of the Betacoronavirus B genetic group, severe acute respiratory syndrome virus 2 (SARS-CoV-2). This new virus shar...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245503/ http://dx.doi.org/10.1016/B978-0-12-823915-5.00014-9 |
Sumario: | Coronavirus disease 2019 (COVID-19) was first detected in December 2019 in China and has caused a global pandemic affecting 202 nations around the world. It is caused by a new pathogen of the Betacoronavirus B genetic group, severe acute respiratory syndrome virus 2 (SARS-CoV-2). This new virus shares 96% similarity in RNA with bat coronavirus and 80% similarity with SARS virus but is severely more transmissible. SARS-CoV-2 has inflicted more than 4.29 million fatalities around the globe, has devastated the global economy, and continues to spread. There has been a tremendous scientific thrust for diagnostics, therapy, and vaccines for SARS-CoV-2. The SARS-CoV-2 virion has a nanoscale structure consisting of four protein components. Therefore, bionanomaterials are key candidates for engineering a therapy and diagnostic to combat this disease. This chapter reviews the advances in bionanomaterial-based disinfectants, therapy, vaccine, and diagnostics for SARS-CoV-2. We will also highlight the key material properties of these novel nanostructures. |
---|